Uni-Bio Science Partners Kexing Biopharm to Commercialize Bogutai in Six Markets; Shares Rise 7%

MT Newswires Live

Sep 15

Uni-Bio Science Group (HKG:0690) said its unit, Beijing Genetech Pharmaceutical, has entered into a strategic cooperation agreement with Kexing Biopharm (SHA:688136) to commercialize its osteoporosis treatment Bogutai, according to a Friday Hong Kong bourse filing.

Shares of the firm were up nearly 7% in Monday morning trade.

The agreement grants Kexing Biopharm exclusive rights to market Bogutai in Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico.

Bogutai, a pre-filled pen-type teriparatide injection launched in China in March 2024, is used for postmenopausal women at high risk of fractures.

The partnership will target markets with more than 10 million osteoporosis patients and an estimated value of nearly $1.5 billion, with revenue expected from late 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2567194040"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2567194040\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2567194040?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-15 10:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2567194040","market":"sg","top_or_hot":-1,"title":"Uni-Bio Science Partners Kexing Biopharm to Commercialize Bogutai in Six Markets; Shares Rise 7%","media":"MT Newswires Live","content":"<html><body><p> Uni-Bio Science Group (HKG:0690) said its unit, Beijing Genetech Pharmaceutical, has entered into a strategic cooperation agreement with <a href=\"https://laohu8.com/S/688136\">Kexing Biopharm</a> (SHA:688136) to commercialize its osteoporosis treatment Bogutai, according to a Friday Hong Kong bourse filing.</p><p>Shares of the firm were up nearly 7% in Monday morning trade.</p><p>The agreement grants Kexing Biopharm exclusive rights to market Bogutai in Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico.</p><p>Bogutai, a pre-filled pen-type teriparatide injection launched in China in March 2024, is used for postmenopausal women at high risk of fractures.</p><p>The partnership will target markets with more than 10 million osteoporosis patients and an estimated value of nearly $1.5 billion, with revenue expected from late 2026.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Uni-Bio Science Partners Kexing Biopharm to Commercialize Bogutai in Six Markets; Shares Rise 7%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUni-Bio Science Partners Kexing Biopharm to Commercialize Bogutai in Six Markets; Shares Rise 7%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-15 10:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Uni-Bio Science Group (HKG:0690) said its unit, Beijing Genetech Pharmaceutical, has entered into a strategic cooperation agreement with <a href=\"https://laohu8.com/S/688136\">Kexing Biopharm</a> (SHA:688136) to commercialize its osteoporosis treatment Bogutai, according to a Friday Hong Kong bourse filing.</p><p>Shares of the firm were up nearly 7% in Monday morning trade.</p><p>The agreement grants Kexing Biopharm exclusive rights to market Bogutai in Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico.</p><p>Bogutai, a pre-filled pen-type teriparatide injection launched in China in March 2024, is used for postmenopausal women at high risk of fractures.</p><p>The partnership will target markets with more than 10 million osteoporosis patients and an estimated value of nearly $1.5 billion, with revenue expected from late 2026.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688136","symbol_name":"科兴制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2567194040","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2567194040","pubTimestamp":1757904230,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Uni-Bio Science Group  said its unit, Beijing Genetech Pharmaceutical, has entered into a strategic cooperation agreement with Kexing Biopharm  to commercialize its osteoporosis treatment Bogutai, according to a Friday Hong Kong bourse filing.Shares of the firm were up nearly 7% in Monday morning trade.The agreement grants Kexing Biopharm exclusive rights to market Bogutai in Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico.Bogutai, a pre-filled pen-type teriparatide injection launched in China in March 2024, is used for postmenopausal women at high risk of fractures.The partnership will target markets with more than 10 million osteoporosis patients and an estimated value of nearly $1.5 billion, with revenue expected from late 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688136":"科兴制药","BK1161":"生物科技","BK0239":"医药制造","00690":"联康生物科技集团"},"translate_title":"Uni-Bio Science与科兴生物制药合作，将博古泰在六个市场商业化；股价上涨7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688136":0.9,"00690":0.9},"content_text":"Uni-Bio Science Group (HKG:0690) said its unit, Beijing Genetech Pharmaceutical, has entered into a strategic cooperation agreement with Kexing Biopharm (SHA:688136) to commercialize its osteoporosis treatment Bogutai, according to a Friday Hong Kong bourse filing.Shares of the firm were up nearly 7% in Monday morning trade.The agreement grants Kexing Biopharm exclusive rights to market Bogutai in Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico.Bogutai, a pre-filled pen-type teriparatide injection launched in China in March 2024, is used for postmenopausal women at high risk of fractures.The partnership will target markets with more than 10 million osteoporosis patients and an estimated value of nearly $1.5 billion, with revenue expected from late 2026.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}